Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 2971 AL 2985

Agreement between clinician-rated versus patient-reported outcomes in Huntington disease

Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai JS, Dayalu P.

J Neurol. 2018 Jun;265(6):1443-1453. doi: 10.1007/s00415-018-8852-5. Epub 2018 Apr 23.

Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease

Loi SM, Walterfang M, Velakoulis D, Looi JC.

Australas Psychiatry. 2018 Aug;26(4):376-380. doi: 10.1177/1039856218766120. Epub 2018 Apr 24.

Rab GTPases and Membrane Trafficking in Neurodegeneration

Kiral FR, Kohrs FE, Jin EJ, Hiesinger PR.

Curr Biol. 2018 Apr 23;28(8):R471-R486. doi: 10.1016/j.cub.2018.02.010.

Retinal dysfunction in a presymptomatic patient with Huntington's disease

Knapp J, VanNasdale DA, Ramsey K, Racine J.

Doc Ophthalmol. 2018 Jun;136(3):213-221. doi: 10.1007/s10633-018-9632-3. Epub 2018 Apr 24.

The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review

Yaribeygi H, Panahi Y, Javadi B, Sahebkar A.

CNS Neurol Disord Drug Targets. 2018;17(3):207-215. doi: 10.2174/1871527317666180425122557.

Age-related neuropathies and tubulin acetylation

Fernández-Barrera J, Correas I, Alonso MA.

Aging (Albany NY). 2018 Apr 28;10(4):524-525. doi: 10.18632/aging.101432.

Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease

Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1.

The adjustment of γ-aminobutyric acid(A) tonic subunits in Huntington's disease: from transcription to translation to synaptic levels into the neostriatum

Rosas-Arellano A, Estrada-Mondragón A, Mantellero CA, Tejeda-Guzmán C, Castro MA.

Neural Regen Res. 2018 Apr;13(4):584-590. doi: 10.4103/1673-5374.230270.

Autophagy in Age-Associated Neurodegeneration

Metaxakis A, Ploumi C, Tavernarakis N.

Cells. 2018 May 5;7(5):37. doi: 10.3390/cells7050037.

Inherited and Acquired Choreas

de Gusmao CM, Waugh JL.

Semin Pediatr Neurol. 2018 Apr;25:42-53. doi: 10.1016/j.spen.2018.01.002. Epub 2018 Feb 23.

Movement Disorders and Neurometabolic Diseases

Christensen CK, Walsh L.

Semin Pediatr Neurol. 2018 Apr;25:82-91. doi: 10.1016/j.spen.2018.02.003. Epub 2018 Feb 14.

Huntington's disease: Current and future therapeutic prospects

Kieburtz K, Reilmann R, Olanow CW.

Mov Disord. 2018 Jul;33(7):1033-1041. doi: 10.1002/mds.27363. Epub 2018 May 8.

Ameliorating the age at onset and disease progression in Huntington disease

Morrison PJ, Delatycki MB.

Neurology. 2018 Jun 12;90(24):1087-1088. doi: 10.1212/WNL.0000000000005670. Epub 2018 May 9.

Old Drugs as New Treatments for Neurodegenerative Diseases

Durães F, Pinto M, Sousa E.

Pharmaceuticals (Basel). 2018 May 11;11(2):44. doi: 10.3390/ph11020044.

Spontaneous Intracranial Hypotension as a Cause of Exacerbation in Huntington's Disease

Figueroa EL, Jog MS, Pelz DM, Lownie SP.

Can J Neurol Sci. 2018 May;45(3):357-359. doi: 10.1017/cjn.2017.296.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias